Lichen  	Lichen  	 JJ	O
planus  	planus  	 JJ	B-NP
secondary  	secondary  	 JJ	I-NP
complications  	complications  	 NNS	I-NP
associated  	associated  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
biologic  	biologic  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
for  	for  	 IN	I-NP
rheumatoid  	rheumatoid  	 FW	I-NP
arthritis  	arthritis  	 FW	I-NP
Biologic  	Biologic  	 FW	I-NP
therapy  	therapy  	 FW	I-NP
such  	such  	 JJ	O
as  	as  	 IN	O
Etanercept 	Etanercept 	 NNP	B-NP
,  	,  	 ,	O
which  	which  	 WDT	O
is  	is  	 VBZ	O
a  	a  	 DT	O
tumor  	tumor  	 NN	B-NP
necrosis  	necrosis  	 NN	I-NP
factor  	factor  	 NN	I-NP
alpha  	alpha  	 NNS	I-NP
( 	( 	 -LRB-	O
TNF-α 	TNF-α 	 NNP	B-NP
)  	)  	 -RRB-	O
inhibitor 	inhibitor 	 NN	O
,  	,  	 ,	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
extensively  	extensively  	 RB	O
used  	used  	 VBN	O
as  	as  	 IN	O
election  	election  	 NN	B-NP
therapy  	therapy  	 NN	I-NP
in  	in  	 IN	O
rheumatoid  	rheumatoid  	 JJ	B-NP
arthritis 	arthritis 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
purpose  	purpose  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
case  	case  	 NN	B-NP
presentation  	presentation  	 NN	I-NP
was  	was  	 VBD	O
to  	to  	 TO	O
inform  	inform  	 VB	O
about  	about  	 IN	O
the  	the  	 DT	O
possibility  	possibility  	 NN	O
that  	that  	 IN	O
lichen  	lichen  	 JJ	O
planus  	planus  	 JJ	B-NP
lesions  	lesions  	 NNS	I-NP
could  	could  	 MD	O
potentially  	potentially  	 RB	O
become  	become  	 VB	O
complicated  	complicated  	 VBN	O
by  	by  	 IN	O
secondary  	secondary  	 JJ	B-NP
infections  	infections  	 NNS	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
Etanercept 	Etanercept 	 NNP	B-NP
.  	.  	 .	O
Furthermore 	Furthermore 	 RB	O
,  	,  	 ,	O
we  	we  	 PRP	O
aimed  	aimed  	 VBD	O
at  	at  	 IN	O
analyzing  	analyzing  	 VBG	O
if  	if  	 IN	O
the  	the  	 DT	O
complication  	complication  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
cutaneous  	cutaneous  	 JJ	I-NP
lesion  	lesion  	 NN	I-NP
was  	was  	 VBD	O
coincidental  	coincidental  	 JJ	O
or  	or  	 CC	O
it  	it  	 PRP	O
was  	was  	 VBD	O
due  	due  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
immunosuppressive  	immunosuppressive  	 JJ	B-NP
systemic  	systemic  	 JJ	I-NP
therapy 	therapy 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
whether  	whether  	 IN	O
the  	the  	 DT	O
infected  	infected  	 JJ	O
lesion  	lesion  	 NN	B-NP
would  	would  	 MD	O
respond  	respond  	 VB	O
to  	to  	 TO	O
antibiotic  	antibiotic  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
patient  	patient  	 NN	O
was  	was  	 VBD	O
a  	a  	 DT	O
59-year-old  	59-year-old  	 JJ	O
woman  	woman  	 NN	O
with  	with  	 IN	O
rheumatoid  	rheumatoid  	 JJ	B-NP
arthritis  	arthritis  	 NN	I-NP
and  	and  	 CC	O
that  	that  	 WDT	O
have  	have  	 VBP	O
had  	had  	 VBN	O
lichen  	lichen  	 JJ	O
planus  	planus  	 JJ	B-NP
lesions  	lesions  	 NNS	I-NP
for  	for  	 IN	O
approximately  	approximately  	 RB	O
25  	25  	 CD	O
years 	years 	 NNS	O
.  	.  	 .	O
Only  	Only  	 RB	O
recently 	recently 	 RB	O
,  	,  	 ,	O
she  	she  	 PRP	O
had  	had  	 VBD	O
been  	been  	 VBN	O
received  	received  	 VBN	O
immunosuppressive  	immunosuppressive  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
( 	( 	 -LRB-	O
Etanercept  	Etanercept  	 NNP	B-NP
and  	and  	 CC	O
Methotrexate 	Methotrexate 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Further  	Further  	 RBR	O
on 	on 	 IN	O
,  	,  	 ,	O
the  	the  	 DT	O
lichen  	lichen  	 JJ	B-NP
planus  	planus  	 NNS	I-NP
flared  	flared  	 VBN	O
up  	up  	 RP	O
with  	with  	 IN	O
a  	a  	 DT	O
secondary  	secondary  	 JJ	B-NP
infection  	infection  	 NN	I-NP
determined  	determined  	 VBN	O
by  	by  	 IN	O
a  	a  	 DT	O
Methicillin-sensitive  	Methicillin-sensitive  	 JJ	B-NP
Staphylococcus  	Staphylococcus  	 JJ	I-NP
aureus 	aureus 	 NN	I-NP
.  	.  	 .	O
Uncommon  	Uncommon  	 JJ	B-NP
myocardial  	myocardial  	 JJ	I-NP
complications  	complications  	 NNS	I-NP
were  	were  	 VBD	O
also  	also  	 RB	O
characteristic  	characteristic  	 JJ	O
of  	of  	 IN	O
this  	this  	 DT	O
case 	case 	 NN	O
.  	.  	 .	O
While  	While  	 IN	O
a  	a  	 DT	O
case  	case  	 NN	B-NP
report  	report  	 NN	I-NP
described  	described  	 VBD	O
already  	already  	 RB	O
the  	the  	 DT	O
appearance  	appearance  	 NN	O
of  	of  	 IN	O
lichen  	lichen  	 JJ	B-NP
planus  	planus  	 NNS	I-NP
following  	following  	 VBG	O
Etanercept  	Etanercept  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
( 	( 	 -LRB-	O
Battistella  	Battistella  	 NNP	B-NP
M  	M  	 NNP	I-NP
et  	et  	 NNP	O
al. 	al. 	 NNP	O
,  	,  	 ,	O
2008 	2008 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
the  	the  	 DT	O
possibility  	possibility  	 NN	O
that  	that  	 IN	O
the  	the  	 DT	O
lesion  	lesion  	 NN	B-NP
could  	could  	 MD	O
become  	become  	 VB	O
secondary  	secondary  	 JJ	B-NP
complicated  	complicated  	 JJ	I-NP
following  	following  	 VBG	O
this  	this  	 DT	O
therapy  	therapy  	 NN	O
was  	was  	 VBD	O
never  	never  	 RB	O
reported  	reported  	 VBD	O
before 	before 	 RB	O
,  	,  	 ,	O
according  	according  	 VBG	O
to  	to  	 TO	O
our  	our  	 PRP$	O
knowledge 	knowledge 	 NN	O
.  	.  	 .	O
Additionally 	Additionally 	 RB	O
,  	,  	 ,	O
we  	we  	 PRP	O
describe  	describe  	 VBP	O
in  	in  	 IN	O
this  	this  	 DT	O
case  	case  	 NN	O
the  	the  	 DT	O
interplay  	interplay  	 NN	O
between  	between  	 IN	O
Etanercept  	Etanercept  	 NNP	B-NP
therapy  	therapy  	 NN	I-NP
and  	and  	 CC	O
hypertrophic  	hypertrophic  	 JJ	B-NP
cardiomyopathy 	cardiomyopathy 	 NN	I-NP
.  	.  	 .	O
Our  	Our  	 PRP$	O
case  	case  	 NN	O
is  	is  	 VBZ	O
not  	not  	 RB	O
a  	a  	 DT	O
lichen  	lichen  	 JJ	O
planus  	planus  	 JJ	B-NP
induced  	induced  	 NN	I-NP
by  	by  	 IN	O
Etanercept 	Etanercept 	 NNP	B-NP
,  	,  	 ,	O
but  	but  	 CC	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
aggravated  	aggravated  	 VBN	O
and  	and  	 CC	O
secondary  	secondary  	 JJ	B-NP
infected  	infected  	 NN	I-NP
with  	with  	 IN	O
Methicillin-sensitive  	Methicillin-sensitive  	 NNP	B-NP
Staphylococcus  	Staphylococcus  	 NNP	I-NP
during  	during  	 IN	O
the  	the  	 DT	O
therapy 	therapy 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
additional  	additional  	 JJ	O
cardiac  	cardiac  	 JJ	B-NP
complication  	complication  	 NN	I-NP
( 	( 	 -LRB-	O
hypertrophic  	hypertrophic  	 FW	B-NP
cardiomyopathy 	cardiomyopathy 	 FW	I-NP
)  	)  	 -RRB-	O
may  	may  	 MD	O
represent  	represent  	 VB	O
solely  	solely  	 RB	O
an  	an  	 DT	O
evolutive  	evolutive  	 JJ	B-NP
sign  	sign  	 NN	I-NP
of  	of  	 IN	I-NP
rheumatoid  	rheumatoid  	 JJ	I-NP
arthritis  	arthritis  	 NN	I-NP
and  	and  	 CC	O
therefore  	therefore  	 RB	O
not  	not  	 RB	O
influenced  	influenced  	 VBN	O
by  	by  	 IN	O
Etanercept 	Etanercept 	 NNP	B-NP
.  	.  	 .	O
